Fig. 2
Monthly costsa for patients with HCC previously treated with sorafenib (subgroups #3b and #4c). aAt values reported for each index year 2012 to 2014; all patients who were insured for at least one day in the corresponding month contributed to costs. bPatients who died within the observation period but not under sorafenib therapy (i.e. more than 70 days between the last sorafenib prescription and death). cPatients who were still alive at the end of the observation period and for whom at least 70 days had passed between the last prescription of sorafenib and the end of the observation period. HCC hepatocellular carcinoma